Grown Rogue International (GRUSF) Share-based Compensation (2012 - 2026)
Grown Rogue International (GRUSF) posted quarterly Share-based Compensation of $154994.0 for Q1 2026, down 89.21% year-over-year from $1.4 million in Q1 2025, and up 100.0% quarter-over-quarter from -$1969.7 billion in Q4 2025.
Grown Rogue International (GRUSF) Share-based Compensation (2012 - 2026) Analysis & Trends
Grown Rogue International's Share-based Compensation history runs 14 years deep, the most recent figure standing at $154994.0 for Q1 2026.
- In Q1 2026, Share-based Compensation fell 89.21% year-over-year to $154994.0; the TTM figure through Mar 2026 stood at -$157635.0 (up 100.0% YoY), while the FY2025 annual figure was $1.1 million, down 30.18% from the prior year.
- Share-based Compensation for Q1 2026 stood at $154994.0, up from -$1969.7 billion in the prior quarter.
- The five-year high for Share-based Compensation was $1969.7 billion in Q3 2025, with the low at -$1969.7 billion in Q4 2025.
- The 5-year median for Share-based Compensation is $75874.0 (2023), against an average of -$27.1 billion.
- Peak annual rise in Share-based Compensation reached 911452470.55% in 2025, while the deepest fall reached 419.48% in 2025.
- Grown Rogue International's Share-based Compensation stood at $7499.0 in 2022, then soared by 3773.73% to $290491.0 in 2023, then slumped by 130529579.8% to -$379.2 billion in 2024, then tumbled by 419.48% to -$1969.7 billion in 2025, then jumped by 100.0% to $154994.0 in 2026.
- Business Quant data shows GRUSF's Share-based Compensation at $154994.0 in Q1 2026, -$1969.7 billion in Q4 2025, and $1969.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Grown Rogue International | 109.32 Mn | 97.78 Mn | 5.37 Mn | 149,087.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 149,087.00 |
| Jun 30, 2026 | 149,087.00 |
| Mar 31, 2026 | 154,994.00 |
| Mar 31, 2026 | 154,994.00 |
| Dec 31, 2025 | -1,969.73 Bn |
| Dec 31, 2025 | -1,969.73 Bn |
| Sep 30, 2025 | 1,969.73 Bn |
| Sep 30, 2025 | 1,969.73 Bn |
| Jun 30, 2025 | 6,433.00 |
| Jun 30, 2025 | 6,433.00 |
| Mar 31, 2025 | 1.44 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | -379.18 Bn |
| Dec 31, 2024 | -379.18 Bn |
| Sep 30, 2024 | 216,109.28 |
| Sep 30, 2024 | 216,109.28 |
| Jun 30, 2024 | 20,607.93 |
| Jun 30, 2024 | 20,607.93 |
| Mar 31, 2024 | 56,185.00 |
| Mar 31, 2024 | 56,185.00 |